title: Inhibin and the regulation of bone mass.
abstract: Inhibins A and B are gonadal peptide members of the transforming growth factor-beta superfamily that serve as negative feedback regulators of pituitary follicle-stimulating hormone (FSH). Accumulating evidence suggests that bone turnover and bone loss increase in women before menopause and the decrease in serum estradiol levels. Increased FSH levels have been correlated with some of these perimenopausal changes, whereas decreased inhibins strongly correlate with increases in bone formation and resorption across the menopause transition, and predict lumbar bone mass in perimenopausal women, likely resulting from the direct inhibin suppression of osteoblast and osteoclast development. Interestingly, continuous exposure of mice to inhibin A in vivo is anabolic and protective against gonadectomy-induced bone loss. Together, these data suggest inhibins contribute to the endocrine regulation of bone metabolism via a bimodal mechanism of action such that cycling inhibin exposure suppresses bone turnover, and continuous exposure to inhibins is anabolic.
authors.affiliation: Department of Physiology, University of Arkansas for Medical Sciences, 4301 W. Markham, Slot 505, Little Rock, AR 72205, USA. gaddydana@uams.edu
authors.forename: Dana
authors.initials: D
authors.lastname: Gaddy
mesh_terms: D000818:Animals; D015519:Bone Density / Q000502:physiology*; D001842:Bone and Bones / Q000378:metabolism*; D004195:Disease Models, Animal; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006801:Humans; D007265:Inhibins / Q000502:physiology*; D051379:Mice; D015663:Osteoporosis, Postmenopausal / Q000378:metabolism
chemical_list: D007265:Inhibins; D005640:Follicle Stimulating Hormone
references.citation: J Biol Chem. 2008 Mar 21;283(12):7628-37
references.pmid: 18184661
references.citation: Semin Reprod Med. 2004 Aug;22(3):269-76
references.pmid: 15319829
references.citation: Endocrine. 2002 Feb;17(1):29-36
references.pmid: 12014700
references.citation: J Clin Endocrinol Metab. 1996 Jul;81(7):2742-5
references.pmid: 8675606
references.citation: Bone. 1999 Feb;24(2):121-4
references.pmid: 9951780
references.citation: Nature. 2000 Mar 23;404(6776):411-4
references.pmid: 10746731
references.citation: Metabolism. 1976 Aug;25(8):909-55
references.pmid: 181659
references.citation: Novartis Found Symp. 2002;242:247-59; discussion 260-4
references.pmid: 11855691
references.citation: J Clin Endocrinol Metab. 1998 Jul;83(7):2266-74
references.pmid: 9661593
references.citation: Endocrinology. 2002 Jan;143(1):74-83
references.pmid: 11751595
references.citation: J Clin Endocrinol Metab. 1999 Jan;84(1):105-11
references.pmid: 9920069
references.citation: Osteoporos Int. 1998;8(3):282-90
references.pmid: 9797914
references.citation: J Clin Endocrinol Metab. 1996 Apr;81(4):1401-5
references.pmid: 8636341
references.citation: Ann N Y Acad Sci. 2004 Dec;1038:142-7
references.pmid: 15838109
references.citation: J Biol Chem. 2001 May 4;276(18):14588-96
references.pmid: 11278442
references.citation: Trends Mol Med. 2005 Feb;11(2):76-81
references.pmid: 15694870
references.citation: Mol Cell Biol. 1991 Jan;11(1):250-8
references.pmid: 1846021
references.citation: J Bone Miner Res. 1999 Feb;14(2):178-86
references.pmid: 9933470
references.citation: J Clin Invest. 2006 Aug;116(8):2152-60
references.pmid: 16878176
references.citation: Endocrinology. 2004 Apr;145(4):1835-41
references.pmid: 14691012
references.citation: Endocrinology. 2006 Dec;147(12):5592-9
references.pmid: 16935844
references.citation: J Bone Miner Res. 2008 Feb;23(2):205-14
references.pmid: 17937534
references.citation: Mol Endocrinol. 1997 Nov;11(12):1832-45
references.pmid: 9369451
references.citation: Mol Cell Endocrinol. 2004 Oct 15;225(1-2):29-36
references.pmid: 15451565
references.citation: J Clin Invest. 1998 Jul 15;102(2):274-82
references.pmid: 9664068
references.citation: J Clin Endocrinol Metab. 2006 May;91(5):1848-54
references.pmid: 16449331
references.citation: Mol Endocrinol. 2000 Jul;14(7):1075-85
references.pmid: 10894156
references.citation: Recent Prog Horm Res. 2002;57:385-409
references.pmid: 12017554
references.citation: J Endocrinol. 2005 Dec;187(3):311-25
references.pmid: 16423810
references.citation: J Clin Endocrinol Metab. 1996 Sep;81(9):3366-71
references.pmid: 8784098
references.citation: Cell. 2006 Apr 21;125(2):247-60
references.pmid: 16630814
references.citation: J Bone Miner Res. 1996 Apr;11(4):440-5
references.pmid: 8992874
references.citation: Maturitas. 2005 Oct 16;52(2):147-53
references.pmid: 16186077
references.citation: Cell Struct Funct. 1995 Oct;20(5):319-30
references.pmid: 8581988
references.citation: Endocrinology. 2006 Jul;147(7):3462-71
references.pmid: 16601134
references.citation: J Clin Endocrinol Metab. 1997 May;82(5):1522-7
references.pmid: 9141544
references.citation: Recent Prog Horm Res. 2002;57:257-75
references.pmid: 12017547
references.citation: Curr Opin Pharmacol. 2005 Dec;5(6):612-7
references.pmid: 16181808
references.citation: J Bone Miner Res. 2004 Dec;19(12):1945-54
references.pmid: 15537436
references.citation: Endocr Rev. 2000 Apr;21(2):115-37
references.pmid: 10782361
references.citation: J Biol Chem. 1988 Nov 25;263(33):17225-8
references.pmid: 2903159
references.citation: Mayo Clin Proc. 2000 Jan;75 Suppl:S46-50
references.pmid: 10959216
references.citation: Endocrinology. 2007 Apr;148(4):1654-65
references.pmid: 17194739